Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer

PHASE2UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 11, 2019

Primary Completion Date

March 31, 2021

Study Completion Date

May 1, 2022

Conditions

HER2-positive Breast Cancer

Interventions

DRUG

pegylated liposomal doxorubicin

Eligible patients will be treated with the PLD+trastuzumab regimen until the disease progresses or intolerable toxicity

Trial Locations (1)

RECRUITING

Peng Yuan, Beijing